Published in Ther Drug Monit on January 01, 1985
Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. Afr Health Sci (2003) 1.74
Colorimetric and thin-layer chromatographic methods for field assay of chloroquine and its metabolites in urine. Bull World Health Organ (1987) 0.93
Rapid DNA extraction from dried blood spots on filter paper: potential applications in biobanking. Osong Public Health Res Perspect (2014) 0.85
Imported malaria in United Arab Emirates: evaluation of a new DNA extraction technique using nested PCR. Korean J Parasitol (2009) 0.81
A specific ELISA method for determining chloroquine in urine or dried blood spots. Bull World Health Organ (1988) 0.78
Is "dried stool spots on filter paper method (DSSFP)" more sensitive and effective for detecting Blastocystis spp. and their subtypes by PCR and sequencing? Parasitol Res (2016) 0.76
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr (1982) 2.40
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand (1976) 2.34
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Toxicological studies on omeprazole. Scand J Gastroenterol Suppl (1985) 2.19
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci (1967) 2.05
Chloroquine-resistant falciparum malaria in Madagascar and Kenya. Ann Trop Med Parasitol (1981) 2.03
Factors affecting auditory performance of postlinguistically deaf adults using cochlear implants. Audiol Neurootol (1997) 2.03
[Tetanus with a deep wound?]. Lakartidningen (1994) 1.92
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. J Clin Pharm Ther (2003) 1.71
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother (1982) 1.65
Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health (1996) 1.65
Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg (1992) 1.63
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
The concentration of chloroquine in serum during short and long term malaria prophylaxis with standard and 'double' dosage in non-immunes: clinical implications. Ann Trop Med Parasitol (1979) 1.51
Clofazimine. A new agent for the treatment of pyoderma gangrenosum. Arch Dermatol (1976) 1.50
Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol (1981) 1.49
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet (1982) 1.46
A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 1.46
Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol (1972) 1.43
Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ (1987) 1.43
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
Metabolism of methyl mercury (203Hg) compounds in man. Arch Environ Health (1969) 1.38
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol (1998) 1.35
On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther (1983) 1.34
Making healthy choices easy choices: the role of empowerment. Eur J Clin Nutr (2005) 1.32
New possibilities for adrenergic modulation of ganglionic transmission. Pharmacol Rev (1966) 1.32
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1975) 1.30
A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer (1978) 1.29
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther (2001) 1.25
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Effects on leg muscular performance from whole-body vibration exercise: a systematic review. Scand J Med Sci Sports (2006) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and beta-thalassaemia traits. Ann Trop Med Parasitol (1983) 1.24
Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol (1997) 1.23
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol (1985) 1.22
Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther (1985) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol (1979) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Changes in erythrocyte sedimentation rate, C-reactive protein and hematological parameters in patients with acute malaria. Scand J Infect Dis (1989) 1.20
Biotransformation of terodiline. III. Opposed stereoselectivity in the benzylic and aromatic hydroxylations in rat liver microsomes. Xenobiotica (1987) 1.20
Different malaria control activities in an area of Liberia--effects on malariometric parameters. Ann Trop Med Parasitol (1985) 1.19
Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J Immunol (1989) 1.18
Normal human lens - the distribution of protein. Exp Eye Res (1981) 1.16
On the fate of furosemide in man. Eur J Clin Pharmacol (1975) 1.15
Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J Immunol (1995) 1.14
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther (1998) 1.11
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol (1987) 1.11
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol (1999) 1.10
Determination of furosemide concentrations in plasma and urine using high-speed liquid chromatography. J Chromatogr (1974) 1.09
Pharmacokinetics of fluoride in man after single and multiple oral doses. Eur J Clin Pharmacol (1977) 1.09